Selected article for: "disease onset and high level"

Author: Molnar, Tihamer; Varnai, Reka; Schranz, Daniel; Zavori, Laszlo; Peterfi, Zoltan; Sipos, David; Tőkés-Füzesi, Margit; Illes, Zsolt; Buki, Andras; Csecsei, Peter
Title: Severe Fatigue and Memory Impairment Are Associated with Lower Serum Level of Anti-SARS-CoV-2 Antibodies in Patients with Post-COVID Symptoms
  • Cord-id: mai3u5cl
  • Document date: 2021_9_23
  • ID: mai3u5cl
    Snippet: Background: Post-COVID manifestation is defined as persistent symptoms or long-term complications beyond 4 weeks from disease onset. Fatigue and memory impairment are common post-COVID symptoms. We aimed to explore associations between the timeline and severity of post-COVID fatigue and anti-SARS-CoV-2 antibodies. Methods: Fatigue and memory impairment were assessed in a total of 101 post-COVID subjects using the Chalder fatigue scale (CFQ-11) and a visual analogue scale. Using the bimodal scori
    Document: Background: Post-COVID manifestation is defined as persistent symptoms or long-term complications beyond 4 weeks from disease onset. Fatigue and memory impairment are common post-COVID symptoms. We aimed to explore associations between the timeline and severity of post-COVID fatigue and anti-SARS-CoV-2 antibodies. Methods: Fatigue and memory impairment were assessed in a total of 101 post-COVID subjects using the Chalder fatigue scale (CFQ-11) and a visual analogue scale. Using the bimodal scoring system generated from CFQ-11, a score ≥4 was defined as severe fatigue. Serum anti-SARS-CoV-2 spike (anti-S-Ig) and nucleocapsid (anti-NC-Ig) antibodies were examined at two time points: 4–12 weeks after onset of symptoms, and beyond 12 weeks. Results: The serum level of anti-S-Ig was significantly higher in patients with non-severe fatigue compared to those with severe fatigue at 4–12 weeks (p = 0.006) and beyond 12 weeks (p = 0.016). The serum level of anti-NC-Ig remained high in patients with non-severe fatigue at both time points. In contrast, anti-NC-Ig decreased significantly in severe fatigue cases regardless of the elapsed time (4–12 weeks: p = 0.024; beyond 12 weeks: p = 0.005). The incidence of memory impairment was significantly correlated with lower anti-S-Ig levels (−0.359, p < 0.001). Conclusion: The systemic immune response reflected by antibodies to SARS-CoV-2 is strongly correlated with the severity of post-COVID fatigue.

    Search related documents:
    Co phrase search for related documents
    • acid dehydrogenase and logistic regression analysis: 1, 2
    • active malignant and acute disease: 1
    • acute coronary syndrome and admission symptom: 1, 2
    • acute coronary syndrome and logistic regression analysis: 1, 2, 3, 4
    • acute coronary syndrome and logistic regression model: 1, 2
    • acute coronary syndrome and longitudinal study: 1
    • acute disease and admission symptom: 1, 2, 3, 4, 5, 6, 7
    • acute disease and logistic regression analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50
    • acute disease and logistic regression model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35
    • acute disease and longitudinal study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute illness and admission symptom: 1, 2, 3, 4
    • acute illness and logistic regression analysis: 1, 2, 3, 4, 5, 6, 7
    • acute illness and logistic regression model: 1, 2, 3, 4, 5
    • acute illness and longitudinal setting: 1
    • acute illness and longitudinal study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • acute illness severity and longitudinal study: 1, 2, 3
    • acute phase and logistic regression analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute phase and logistic regression model: 1, 2, 3, 4, 5
    • acute phase and longitudinal study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10